secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K/A
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001104659-22-117504
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma completes sale of TRC units to Royalty Pharma for $1.107 billion cash
--------------------------------------------------------------------------------

- Sold 2,125 Class B and 6,375 Class C units of Theravance Respiratory Company to Royalty Pharma on July 20, 2022.
- Total cash consideration of $1.107 billion, net of $420 million payoff of 9.5% non-recourse notes due 2035.
- Pro forma net gain of approximately $931.8 million recorded, with estimated income tax payable of $120.6 million.
- Pro forma financials show elimination of $148.3 million equity investment and $396.1 million non-recourse notes.
- Transaction qualifies as discontinued operations; pro forma net loss of $68.1 million for six months ended June 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465922117504/0001104659-22-117504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465922117504/tm2229804d4_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer